Advertisement
New Zealand markets close in 3 hours 51 minutes
  • NZX 50

    11,850.28
    +47.00 (+0.40%)
     
  • NZD/USD

    0.5945
    +0.0011 (+0.18%)
     
  • NZD/EUR

    0.5548
    +0.0007 (+0.13%)
     
  • ALL ORDS

    7,968.20
    +30.30 (+0.38%)
     
  • ASX 200

    7,713.40
    +29.90 (+0.39%)
     
  • OIL

    83.45
    +0.09 (+0.11%)
     
  • GOLD

    2,334.40
    -7.70 (-0.33%)
     
  • NASDAQ

    17,471.47
    +260.59 (+1.51%)
     
  • FTSE

    8,044.81
    +20.94 (+0.26%)
     
  • Dow Jones

    38,503.69
    +263.71 (+0.69%)
     
  • DAX

    18,137.65
    +276.85 (+1.55%)
     
  • Hang Seng

    16,828.93
    +317.24 (+1.92%)
     
  • NIKKEI 225

    38,283.23
    +731.07 (+1.95%)
     
  • NZD/JPY

    91.9440
    +0.1780 (+0.19%)
     

Is Biogen Stock a No-Brainer Buy After Eli Lilly's Alzheimer's Disease Setback?

Is Biogen Stock a No-Brainer Buy After Eli Lilly's Alzheimer's Disease Setback?

Lilly's FDA rejection puts Biogen and its partner Eisai in the driver's seat in the Alzheimer's disease drug market.